<DOC>
	<DOCNO>NCT02957435</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics profile formulation eplerenone coat tablet concentration 25mg , 50mg 100mg ( 2 coat tablet 50mg ) male female healthy subject fast condition .</brief_summary>
	<brief_title>Pharmacokinetics Study Eplerenone Coated Tablets</brief_title>
	<detailed_description>This phase I study eplerenone coat tablet 25mg , 50mg 100mg ( 2 coat tablet 50mg ) fast administration . Sample size 12 subject , male female , age 18 50 year old . This open-label , unicenter study three period , three treatment one sequence . Each subject receive follow treatment follow period : - Period 1 : one coat tablet eplerenone 25mg fast - Period 2 : one coat tablet eplerenone 50mg fast - Period 3 : two coat tablet eplerenone 50mg ( 100mg eplerenone ) fasting Formulations administer single dose , orally period . Trial subject admit three different period 24 hour , investigational product administer blood sample collect pre-determined period time pharmacokinetics evaluation . Primary objective evaluate pharmacokinetics formulation eplerenone coat tablet 25mg , 50mg 100mg ( two coat tablet 50mg ) healthy subject fast condition . As secondary objective , also evaluate safe tolerability coat tablet eplerenone .</detailed_description>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Male female subject , age 18 50 year old ; Body mass index ( BMI ) 18.5 30 kg/m2 ; Good health condition without significant disease , investigator discretion , accord protocol evaluation perform : clinical history , vital sign , physical examination , electrocardiogram ( ECG ) laboratory exam ; Ability understand nature objective trial , include risk adverse effect . Know hypersensitivity investigational product ( eplerenone ) chemically related compound ; History presence chronic hepatic gastrointestinal disease , condition may interfere drug absorption , distribution , metabolism excretion ; Be use maintenance therapy drug interfere investigational product , except oral contraceptive ; History hepatic , kidney , lung , gastrointestinal , epileptic , hematologic , psychiatric disease , hypertension etiology , history myocardial infarction , angina and/or heart failure malignant neoplasia , word , current disease , acute chronic , monitor treatment ; Electrocardiographic finding investigator discretion recommend study participation ; History cardiac surgery , kidney surgery ( exeresis kidney anegesis ) , intestinal ( partial full ablation esophagus , stomach , duodenum , jejunum , ileum , ascend colon , transverse colon , descend colon , sigmoid rectum ) liver pancreas surgery ; Laboratory exams result range consider normal accordance reference range stipulate clinical laboratory , unless consider clinically significant investigator ) ; Be smoker ; Ingestion food contains xanthine include five cup coffee tea per day ; Vegan habit ; History abusive use drug and/or alcohol excessive alcohol consumption ; Have use regular medication two week prior start treatment date evaluation use medication one week , except contraceptive case , base halflife drug and/or active metabolite may assume complete elimination ; Have hospitalize reason 8 week prior start first period trial treatment ; Have receive treatment drug know wellestablished toxic potential major organ inside 3 month prior study ; Have participate experimental trial ingest investigational drug within 12 month prior trial start ; Be pregnant breastfeed period want get pregnant study period ; Have donate lose 450 mL blood within 3 month prior trial donation 1500 mL blood within 12 month prior trial ; Have condition , prohibit subject participate trial , investigator 's discretion ; Have difficulty swallow medicine and/or approximately 200 mL water morning ; Inability keep awake seat one hour necessary time investigator discretion ; Present positive pregnancy test ; Present breathalyzer test high zero ; Present positive result preliminary test drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>